Remdesivir prevents MERS coronavirus disease in monkeys

(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news

Related Links:

President Donald Trump’s declaration of a national emergency is designed to speed federal support to parts of America that are struggling to prepare for a coming surge of COVID-19 cases, unlocking $50 billion in aid, giving hospitals and doctors more freedom to handle a potential tsunami of sick patients and scrambling to make tests available. In a Rose Garden press conference Friday, Trump presented the emergency measures as proof that, “No nation is more prepared or more equipped to face down this crisis.” But for epidemiologists, medical experts and current and former U.S. public health officials, the ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
This study, says Kalil, is also designed to be more flexible than most drug trials. “This is not just a remdesivir trial,” he says. “It will test as many [COVID-19] therapies as possible, and remdesivir is just the first. Let’s say a couple of months from now, we realize that remdesivir is a good drug, that it works better than placebo…. Then patients receiving the placebo would be offered the drug and we would move on to test another drug. If remdesivir turns out not to be effective, then we would remove it from the study and bring another drug to test against placebo. It’s a dynamic, ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Infectious Disease Source Type: news
Moderna Therapeutics, a biotech company based in Cambridge, Mass., has shipped the first batches of its COVID-19 vaccine. The vaccine was created just 42 days after the genetic sequence of the COVID_19 virus, called SARS-CoV-2, was released by Chinese researchers in mid-January. The first vials were sent to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in Bethesda, MD, which will ready the vaccine for human testing as early as April. NIH scientists also began testing an antiviral drug called remdesivir that had been developed for Ebola, on a patient infec...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
While the threat of the new coronavirus in the United States remains limited, a network of U.S. government agencies are already furiously ramping up efforts to contain the disease, should an outbreak occur. “We are working to keep the risk low,” said Health and Human Services Secretary Alex Azar, who is leading the federal government’s response, at a press conference Friday. So far, the overwhelming number of new cases of the virus, which originated in Wuhan, China, remain in China. There are only 11 confirmed cases in the U.S. The good news, some officials and infectious disease experts tell TIME, is t...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
The time to prevent more epidemics is now, and countries are trying to seize the moment.
Source: NYT - Category: American Health Authors: Tags: Epidemics Coronavirus (2019-nCoV) SARS (Severe Acute Respiratory Syndrome) MERS (Middle East Respiratory Syndrome) Viruses Centers for Disease Control and Prevention National Institute of Allergy and Infectious Diseases World Health Organiza Source Type: news
Chinese officials confirmed Wednesday that the number of people infected by a new form of coronavirus in the country has reached 5,974, a total that surpasses the official cases tallied on the mainland during an outbreak of severe acute respiratory syndrome (SARS) in 2002 and 2003. SARS infected 5,237 people in mainland China, and killed almost 800 people across the world. The new SARS-like form of coronavirus has killed 132 people in China. The disease, which is believed to have originated in a seafood market in the Chinese central city of Wuhan, has also spread to other countries, including the U.S., where five cases hav...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized China Infectious Disease onetime overnight Source Type: news
Cases of a novel pneumonia-like illness that originated in Wuhan, China in December have now been confirmed in South Korea, Thailand, Japan, Taiwan, Macau—and, as of Jan. 21, the U.S. The virus’ geographic reach, as well as its newly discovered ability to spread via person-to-person contact, has health officials worried about the prospect of globals spread. As health officials scramble to learn more about the virus and is origins, researchers are simultaneously turning to the question of how to develop a vaccine or therapy that could help contain transmission worldwide—a feat that experts say is technical...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
Yíngyún Caì1†, Shuǐqìng Yú1†, Rohit K. Jangra2, Elena N. Postnikova1, Jiro Wada1, Robert B. Tesh3, Sean P. J. Whelan4, Michael Lauck5, Michael R. Wiley6, Courtney L. Finch1, Sheli R. Radoshitzky6, David H. O’Connor5, Gustavo Palacios6, Kartik Chandran2, Charles Y. Chiu7 and Jens H. Kuhn1* 1Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States 2Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States 3Depart...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ~35% mortality. Currently there are no prophylactic measures or effective therapies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. This invention describes antibodies that target the Spike (S) glycoprotein on the coronavirus surface, which mediates viral entry into host cells. These novel antibodies target different regions of the S protein, and when administered in combin...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic approaches.CoV spike (S) prote...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Allergy | Allergy & Immunology | Coronavirus | Infectious Diseases | MERS | Middle East Health | National Institutes of Health (NIH) | Respiratory Medicine | Study